This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Hess, Juniper, Dow Chem: Analysts' New Ratings

Stock quotes in this article: JNPR, LII, IPI, MANT, CSCO, DOW, AGU

Editor's Note: Green and red arrows refer to intraday stock price movement.

NEW YORK ( TheStreet) -- CHANGE IN RATINGS

Agrium (AGU) downgraded at BofA Merrill from Buy to Neutral. $99 price target. Macro uncertainty, deal risks offset fundamental strength.

Arthur J. Gallagher (AJG) upgraded at Brean from Hold to Buy. $35 price target. Company should see better rate momentum.

Cisco Systems (CSCO) upgraded at Goldman to Buy. $21 price target. Street estimates may not be too conservative.

Citrix Sytems (CTXS) upgraded at Morgan Stanley to Overweight. Stock is attractive, following a 24% decline since early June. $88 price target.

Dow Chemical (DOW) upgraded at BofA Merrill from Underperform to Neutral. $42 price target. Solid guidance and strong risk/reward profile.

The Gap (GPS) upgraded at Jefferies from Neutral to Buy. $25 price target. Valuation call as EPS expectations are low and sentiment negative.

Hess (HES) downgraded at Deutsche Bank from Buy to Hold. $75 price target. Lack of significant near term catalysts.

Intrepid Potash (IPI) upgraded at BofA Merrill from Neutral to Buy. $42 price target. Potash market set to strengthen, major catalysts at hand.

Juniper (JNPR) downgraded at Citigroup from Buy to Hold. $27 price target. Weaker than expected results and long term growth remains cloudy.

Lennox (LII) downgraded at UBS from Buy to Neutral. $38 price target. Lower visibility and revised outlook not clearly "beatable."

ManTech (MANT) downgraded at Credit Suisse from Neutral to Underperform. $34 price target. Rising risk and uncertainty in the federal funding environment.

Nextera Energy (NEE) downgraded at Baird to Neutral. Valuation call, based on a $59 price target.

Varian Medical (VAR) downgraded at Baird to Neutral from Outperform, Robert Baird said. $72 price target. Company is seeing lower oncology orders.

Varian Medical numbers lowered at Goldman. Shares of VAR now seen reaching $57, according to Goldman Sachs. Estimates also cut, as the company is realizing slower growth. Sell rating.



End of report.

This article was written by a staff member of TheStreet.

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 16,857.33 -185.57 -1.09%
S&P 500 1,957.27 -15.02 -0.76%
NASDAQ 4,446.0810 -47.3090 -1.05%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs